Energy Expenditure in Japanese Patients with Severe or Moderate Ulcerative Colitis by Sasaki, Masaya et al.
32
Original Article J. Clin. Biochem. Nutr., 47, 32–36, July 2010
JCBN Journal of Clinical Biochemistry and Nutrition 0912-0009 1880-5086 the Society for Free Radical Research Japan Kyoto, Japan jcbn10-07 10.3164/jcbn.10-07 Original Article Energy Expenditure in Japanese Patients with Severe or Moderate 
Ulcerative Colitis
Masaya Sasaki1,*, Tomoko Johtatsu1, Mika Kurihara1, Hiromi Iwakawa1, Toshihiro Tanaka1, 
Shigeki Bamba2, Tomoyuki Tsujikawa2, Yoshihide Fujiyama2 and Akira Andoh3
1Division of Clinical Nutrition, Shiga University of Medical Science, Seta-Tsukinowa, Otsu, Shiga 520-2192, Japan
2Department of Gastroenterology, Shiga University of Medical Science, Seta-Tsukinowa, Otsu, Shiga 520-2192,
Japan
3Division of Mucosal Immunology, Graduate School of Medicine, Shiga University of Medical Science, 
Seta-Tsukinowa, Otsu, Shiga 520-2192, Japan
5 2010 29 4 2010 47 1 ?? ?? Received 12.1.2010 ; accepted 2.2.2010
*To whom correspondence should be addressed.    
Tel: +81-77-548-2217    Fax: +81-77-548-2219    
E-mail: sasaki@belle.shiga-med.ac.jp
Received 12 January, 2010; Accepted 2 February, 2010; Published online 23 April, 2010
Copyright © 2010 JCBN Summary We investigated the energy expenditure in hospitalized patients with severe or
moderate ulcerative colitis (UC), and compared them to healthy controls. Thirteen patients (5
women and 8 men; mean age 31.8 years; mean BMI 19.0 kg/m2) and 10 healthy volunteers
were enrolled in this study. The resting energy expenditure (mREE) levels were determined by
indirect calorimetry. The mREEs of the UC patients were significantly higher than those of
healthy controls (26.4 ± 3.6 vs 21.8 ± 1.7 kcal/kg/day), although the mREEs of the UC patients
were almost the same as the predicted REEs (pREEs) calculated by the Harris-Benedict
equation (26.4 ± 2.4 kcal/kg/day vs 26.5 ± 2.6 kcal/kg/day). The mREE/pREE ratio, which
reflects stress, was 1.0 ± 0.15. In the UC patients, a significant correlation was observed
between the mREEs and the clinical activity index. In conclusion, UC patients showed a hyper-
metabolic status as evaluated by their mREE/body weight. Energy expenditure was signifi-
cantly correlated with disease activity. From our observations, we recommend that nutritional
management with more than 30–35 kcal/ideal body weight/day (calculated by the
mREE × activity factor) may be optimal for active severe or moderate ulcerative colitis.
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Introduction
Ulcerative colitis (UC) is a chronic inflammatory disease
of the digestive tract of unknown etiology [1, 2]. Typical
symptoms include abdominal pain, bloody diarrhea, weight
loss and fever. Patients with UC have various nutrition
deficiencies or metabolic disturbances, although the pre-
valence of nutritional deficiencies or metabolic disturbances
is lower than in patients with Crohn’s disease (CD) [3, 4].
Nutritional support is essential for severe or moderate UC
patients, as well as for CD patients. Corticosteroids and
immunosuppressive drugs are effective in UC patients, but
nutritional therapy such as total parenteral nutrition (TPN) is
integral to the management of UC patients. The aims of
nutritional support in inflammatory bowel disease (IBD) are
to treat or to prevent nutritional deficits, to reduce disease
activity and the need for surgery, and to maintain remission.
An evaluation of the energy expenditure of UC patients is
critical in planning optimal nutritional therapy [5]. Typi-
cally, the total energy of parenteral nutrition or enteral
nutrition is determined by using the predicted resting
expenditure (pREE) calculated by the Harris-Benedict equa-
tion [6], and the total energy requirement is calculated by
pREE × activity factor × stress factor [7]. On the other hand,
the mREE can be determined by indirect calorimetry.Energy Expenditure and Ulcerative Colitis
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There have been several studies reporting that the energy
expenditure of CD patients changes to a hyper-metabolic
status [8–12]. Recently, we have also reported the energy
expenditure of Japanese CD patients [13]. However, there
are a few reports on energy metabolism in adult UC patients
[4, 14, 15]. In this study, we evaluated the energy metabo-
lism of hospitalized UC patients with moderate to severe
clinical activity, and determined the optimal energy require-
ments for nutritional management.
Subjects and Methods
Patients
Thirteen UC patients with moderate to severe clinical
activity (5 women and 8 men, median age 31.8 years old)
and 10 healthy volunteers were enrolled in this study. The
patients were admitted to the Gastroenterology Unit of
Shiga University of Medical Science Hospital. The ethics
committee of the Shiga University of Medical Science
approved this study. All patients had their diagnosis of UC
established by endoscopic, histologic, and clinical criteria.
All patients were defined as the total colitis type, and their
clinical activity index [16] was is 9.8 ± 3.5. Nine patients
were receiving total parenteral nutrition (TPN), and four
patients were receiving peripheral parenteral nutrition
(PPN). Prednisone (30–80 mg/day) was taken by all
patients. Cyclosporine therapy [16, 17] had just been started
in 6 patients, and leukocytapheresis therapy [18] had been
started in one patient.
Indirect calorimetry
The mREEs and respiratory quotients (RQ) were mea-
sured by computed open-circuit indirect calorimetry (AE-
300S; Minato Medical Science Co., Osaka, Japan) [13].
Indirect calorimetry (IC) was performed in the hospital
room on the morning after a 10-h overnight fast in healthy
controls. However, the infusion of parenteral nutrition was
maintained in the UC patients. Period flow and gas calibra-
tion were performed prior to all measurements. After resting
for a minimum of 30 min, the patients were assessed in a
supine position with a facemask. A pump drew ambient air
through a facemask at a constant rate. After equilibrium was
reached for 10 min, respiratory exchange was performed
continuously over 30 min. The mREE and RQ data were
obtained every minute.
The mREE was calculated from the oxygen consumption
(VO2) and carbon dioxide production (VCO2) by the Weir
equation [19]:
mREE = (3.94 × VO2 +1 . 1 1× VCO2) × 1.44
Measurement of the non protein RQ was calculated as
RQ = VCO2/VO2. The measured mREE was then compared
with the pREE (predicted resting energy expenditure] calcu-
lated by the Harris and Benedict equation.:
Men: pREE = 66.47 + 13.75 × W [weight (kg)] + 5.0
× H [height (cm)] − 6.75 × A [age (yrs)].
Women: pREE = 665.09 + 9.56 × W [weight (kg)] + 1.84
× H [height (cm)] − 4.67 × A [age (yrs)].
Statistical analyses
Differences between the groups were analyzed with
Kruskal-Wallis tests. A p value <0.05 was considered to be
statistically significant. Correlations were investigated with
Spearman rank correlation tests.
Results
The patients did not differ significantly from the controls
in their age or height, but had significantly lower body
weights (p<0.01) and lower BMIs (p<0.001) (Table 1).
The average hemoglobin, red blood cell count, white
blood cell count and platelet counts in the UC patients were
10.0 ± 2.1 g/dl, 371.0 ± 81.3 × 104/mm3, 9980 ± 4453/mm2,
33.8 ± 19.5 × 104/mm3 respectively. The serum albumin
and total-cholesterol levels were 2.97 ± 0.47 g/dl and
139.0 ± 51.6 mg/dl, respectively.
The mREE in the UC patients determined by indirect
calorimetry was 1412.5 ± 272.0 kcal/day, and the mREE in
the healthy controls was 1402.7 ± 242.0 kcal/day, respec-
tively. Although the mREE in the UC patients was almost
Table 1. Background of the UC patients and healthy controls
BMI, body mass index.
UC patients controls p value
Patients number 13 10
Female/male 5/8 3/7
Age (y) 31.8 ± 11.7 41.2 ± 18.8 0.155
Height (cm) 168.4 ± 6.6 165.5 ± 8.3 0.360
Body weight (kg) 53.5 ± 7.6 64.5 ± 11.4 0.009
BMI (kg/mm2) 18.8 ± 2.4 23.5 ± 2.3 <0.001M. Sasaki et al.
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the same as in the controls (Table 2), the mREE/body weight
of the UC patients (26.4 ± 3.6 kcal/day) was significantly
higher than that of the controls (21.8 ± 1.7 kcal/day)
(Table 2).
In UC patients, the pREE calculated by the Harris-
Benedict equation was 1407.0 ± 154.0 kcal/day, and there
was a positive correlation between the pREE and mREE
(p<0.05) (Fig. 1). Similar observations were noted in the
controls (p<0.01). The mREE/pREE ratio in the UC patients
(1.00 ± 0.15) was higher than in the controls (0.94 ± 0.10)
(Table 2), but not significant.
The RQ of these patients measured by indirect calorimetry
was 0.92 ± 0.12, and this was significantly higher than the
controls. There was no significant correlation between the
RQ and mREE. There were no significant correlations
between the mREE and BMI, or between the RQ and BMI
in the UC patients.
As shown in Fig. 2, there was a significant positive
correlation between the clinical activity index and the
mREE/body weight ratio. However, there was no significant
correlation between the CRP and mREE/body weight ratio.
Discussion
This is the first report on the resting energy expenditure in
Japanese patients with UC. This study showed that the
mREE measured by IC in hospitalized UC patients was
significantly higher than in healthy controls, indicating a
hyper-metabolic status of the active UC patients. Recently,
we examined the energy metabolism in Japanese CD
patients by indirect calorimetry, and showed that the mREE
of CD patients was 24.4 ± 2.4 kcal/body weight/day [13].
These combined observations suggest that energy metabo-
lism in UC patients was increased to a much greater extent
than in CD patients.
The resting energy expenditure (pREE), calculated by the
Harris-Benedict equation, has been widely used to evaluate
the energy status of patients [5]. The total energy require-
ment is calculated by pREE × activity factor × stress factor
[6]. Theoretically, the pREE is expected to be equal to the
mREE in healthy humans, and the mREE/pREE ratio is a
marker for a hyper-metabolic status [12]. From our results,
the mREE/pREE in the healthy controls and UC patients
Table 2. pREE, mREE, and RQ of UC patients and healthy controls
pREE, predicted resting energy expenditure; mREE, resting energy expenditure measured by indirect calorimetry; RQ,
respiratory quotient.
UC patients controls p value
pREE (kcal/day) 1407.0 ± 154.1 1484.7 ± 233.0 0.347
mREE (kcal/day) 1412.5 ± 272.0 1402.7 ± 242.0 0.930
mREE/pREE (%) 100.2 ± 14.8 94.8 ± 10.2 0.328
pREE/body weight (kcal/kg/day) 26.5 ± 2.6 23.1 ± 2.4 0.003
mREE/body weight (kcal/kg/day) 26.4 ± 3.6 21.8 ± 1.7 0.001
RQ 0.92 ± 0.12 0.83 ± 0.07 0.049
Fig. 1. Correlation between the measured resting energy
expenditure (mREE) and the predicted resting energy
expenditure (pREE). The mREE was measured by
indirect calorimetry, and the pREE was calculated by
the Harris-Benedict equation. There was a positive
correlation between the mREE and pREE in UC patients.
Fig. 2. Correlation between the mREE and disease activity
index in UC patients (n = 13). The mREE in UC patients
exhibited a positive correlation with the disease activity
index.Energy Expenditure and Ulcerative Colitis
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were 94.8 ± 10.2% and 100.2 ± 14.8%, respectively. The
stress factor in patients with IBD is reported to be 1.1–1.3,
similar to patients with cancer or chronic obstructive
pulmonary disease. This adjustment may result in an actual
energy requirement increase of approximately 45 kcal/kg/
day. Energy requirements are often lower than the predicted
requirements if the patients are not very lean with a low
fat mass [4]. Our study suggests that 30–35 kcal/ideal
body weight/day may be optimal for severe or moderate
hospitalized UC patients, and suggests that the calculation
by pREE × active factor × 1.1–1.3 as a stress factor may
be over the energy requirement for active UC patients.
High-energy intakes during TPN therapies also have the risk
of overfeeding.
In this study, we showed that disease activity affected the
energy expenditure in adult UC patients. Proinflammatory
cytokines such as interferon-γ or tumor necrosis factor-α
have been reported to have significant effects on energy
metabolism in patients with systemic inflammatory diseases,
including IBD [20–24]. There was no significant correlation
between the mREE and CRP in our study. Previously,
Wiskin et al. reported that there was no significant correla-
tion between mREE and CRP in children with inflammatory
bowel disease [25], and our present result confirms their
report. The disease activity score and CRP sometimes do not
move in parallel in active UC patients [26, 27]. Osada et al.
reported that clinical symptoms reflected the activity of
distal colon, whereas CRP reflected the activity of proximal
colon [28]. In this study, there was no significant relation-
ship between activity index and CRP in severe or moderate
UC patients.
Previously, it has been reported that the RQ is lowered in
active IBD patients [12, 15]. A reduced RQ means that fat,
but not carbohydrate, is mainly utilized as the fuel substrate,
which resembles a starvation pattern. However, the RQ in
active UC was 0.92 ± 0.12, and was significantly higher than
that in the healthy controls. This unexpected result can be
explained by continuing parenteral nutrition during the
measurements by indirect calorimetry, whereas the healthy
controls were examined after overnight fasting. To deter-
mine the nutritional substrate metabolism in active UC
patients, further studies are necessary in subjects who had
not started parenteral nutrition or steroid therapy.
In conclusion, moderate to severe UC patients have a
hyper-metabolic status, and there is a significant positive
relationship between their resting energy expenditure and
disease activity. From our results, the daily energy require-
ments for Japanese patients with moderate to severe UC are
recommended as 30–35 kcal/ideal body weight.
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